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Effectively Bridging the Preclinical/Clinical
Gap: The Results of the ASTIN Trial
To the Editor:
Recently, the results of the Acute Stroke Therapy by Inhibition
of Neutrophils (ASTIN) were published.1 In this trial, 966
patients presenting within 6 hours of acute stroke received
varying doses of either placebo or UK-279,276, a CD11b/CD18
inhibitor. Additionally, a subgroup of 204 patients was co-
administered tissue plasminogen activator (tPA) when clinically
appropriate. The trial was stopped early when interim analysis
demonstrated futility in achieving the primary end point of
increased functional improvement from the patient’s baseline as
measured by the Scandinavian Stroke Scale (SSS) at 90 days.
Post hoc analysis found that patients co-administered tPA and
UK-279,276 exhibited a mean improvement of 1.6 points on the
SSS, but this study was neither designed nor powered to achieve
statistical significance in this group.
While the study utilized a novel approach to clinical trial
design and management, there are limitations in the design of this
study that, while stated by the authors, merit additional attention.
The first of these is the study’s diminished emphasis on UK-
279,276 as an adjuvant for tPA, with the drug administered as
monotherapy to the majority of patients. Furthermore, evidence
of spontaneous reperfusion (transcranial Doppler, perfusion-
weighted CT) was not used as an inclusion criterion.
Because neuroprotective strategies targeting inflammatory
events such as neutrophil influx primarily aim to attenuate
reperfusion injury, agents such as UK-279,276 would be ex-
pected to demonstrate less efficacy in nonreperfused stroke.2,3
Our own work with CD11b/CD18 established this: CD18 (-/-)
knockout mice were protected in reperfused but not permanent
models of middle cerebral artery occlusion.4
In the current case, preclinical work with UK-279,276 sup-
ported this claim. Early work with the agent using a reperfused
intraluminal suture model with 2 hours of occlusion demon-
strated benefit in the form of decreased infarct volumes and
improved neurological outcomes, but failed to demonstrate
benefit for UK-279,276 when used in a nonreperfused models.5,6
More recently, administration of UK-279,276 was shown to
demonstrate no significant efficacy in a rat model of embolic
stroke when the drug was administered alone, but led to
significantly reduced infarct volumes and improved functional
outcomes when co-administered with tPA, even when adminis-
tered beyond the traditional tPA therapeutic window.7 These data
further strengthened the claim that UK-279,276 predominantly
acts by attenuating cerebral reperfusion injury and as such would
be less likely to improve the neurologic functioning of patients
with lesser degrees of reperfusion.
While future clinical efforts using UK-279,276 and similar
drugs will likely refocus efforts toward subsets of patients who
undergo either spontaneous, pharmacologic, or mechanical
reperfusion, we feel this example further emphasizes the impor-
tance of effectively utilizing strong preclinical data to guide the
design, nature, and aim of clinical stroke trials.8,9 We hope that
closer collaborations formed between basic scientists and clinical
researchers will continue to strengthen the link between preclin-
ical observations and clinical applications in the development of
neuroprotective drugs.
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Response
Drs Sughrue and Connolly correctly point out that the preclin-
ical data indicate that UK-279,276 might potentially be protec-
tive against cerebral reperfusion injury but might not have
neuroprotective properties in the absence of reperfusion. When
designing ASTIN we did debate including measures of cerebral
perfusion and decided against it, mainly for logistical reasons:
perfusion CT was not yet widely available, and overcoming the
technical issues related to establishing tight interrater reliability
of transcranial Doppler measurements appeared a difficult chal-
lenge at the time. However, we entirely agree that quantifying the
degree of perfusion and using it as a covariate of interest is the
way to go in future acute stroke trial exploring compounds that
show promise in reperfusion but not in permanent occlusion
stroke models.
The alternative of limiting the patient population to intrave-
nous tPA–treated patients was also discussed, with a goal to
enrich the proportion of patients with reperfusion. However,
from a sponsor perspective the objective was not to develop an
adjuvant therapy to intravenous tPA but to establish a neuropro-
tective therapy that could benefit the overall set of patients with
ischemic strokes including those who spontaneously reperfused.
The proportion of spontaneous reperfusion within the first 6
hours has been described as 19%1; ie, it seemed reasonable to
allow inclusion of tPA- and non–tPA-treated patients.
Had we known prior to the start of ASTIN that 20% of
patients would be cotreated with intravenous tPA rather than the
5% we anticipated, we would have probably designed a
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different trial. One interpretation of the mean improvement of 1.6
points on the Scandinavian Stroke Scale in the tPA-treated subset
of 204 patients is that it is a pure tPA effect and has nothing to
do with UK-279,276: ASTIN does not allow any conclusions
about interactions between UK-279,276 and tPA.
Given the limitations of the ASTIN trial, it is important to
remember that absence of evidence is not evidence of absence for
the mechanism of action in an appropriately chosen patient
population. An interesting future research question might be
whether an adjuvant therapy to intravenous tPA apart from
potentially improving outcome might also allow to reduce the
overall dose of tPA and thereby potentially add safety benefits.
We are currently developing designs that would allow the
continuous reassessment of the exposure-response and adaptive
allocation to the most promising treatment combination.
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